X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will support the development of the Cartesian pipeline through the Phase 3 study of lead product candidate, Descartes-08, a potential first-in-class RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) for the treatment of myasthenia gravis.
Lead Product(s): Descartes-08
Therapeutic Area: Immunology Product Name: Descartes-08
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Cartesian Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger November 13, 2023
Details:
The combined company will focus on the development of the Cartesian pipeline through the Phase 3 study of lead product candidate, Descartes-08, a potential first-in-class RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) for the treatment of myasthenia gravis.
Lead Product(s): Descartes-08
Therapeutic Area: Immunology Product Name: Descartes-08
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Leerink Partners
Deal Size: $60.2 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 13, 2023
Details:
Sobi will transition the manufacturing and development rights of ImmTOR for SEL-212 to Sobi. SEL-212, a combination of Selecta’s ImmTOR immune tolerance platform and a therapeutic uricase enzyme (pegadricase), is in development for chronic refractory gout.
Lead Product(s): Pegadricase,ImmTOR
Therapeutic Area: Rheumatology Product Name: SEL-212
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Swedish Orphan Biovitrum AB
Deal Size: $705.0 million Upfront Cash: $75.0 million
Deal Type: Licensing Agreement October 31, 2023
Details:
SEL-212 (combination of ImmTOR immune tolerance platform and pegadricase) is designed to reduce serum urate levels in people with chronic refractory gout, potentially reducing harmful tissue urate deposits which causes debilitating gout flares and joint deformity.
Lead Product(s): SEL-037,SEL-110
Therapeutic Area: Rheumatology Product Name: SEL-212
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2023
Details:
SEL-018 (xork) is being studied as a potential next generation immunoglobulin G (IgG) protease that will be developed by Astellas for use with AT845, an investigational, adeno-associated virus (AAV)-based treatment for Late-Onset Pompe disease (LOPD) in adults.
Lead Product(s): Xork,AT845
Therapeutic Area: Genetic Disease Product Name: SEL-018
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: $350.0 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement January 09, 2023
Details:
The selection of a next generation Immunoglobulin A (IgA) protease from IGAN Biosciences for its IgA nephropathy (IgAN) program, will lead Selecta Biosciences to pay IGAN Biosciences.
Lead Product(s): Undisclosed
Therapeutic Area: Nephrology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: IGAN Biosciences
Deal Size: $1.6 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 14, 2022
Details:
SEL-302 is Adeno-Associated Virus (AAV) sterotype which consists of MMA-101 plus ImmTOR for the treatment of patients with methylmalonic acidemia (MMA).
Lead Product(s): SEL-302
Therapeutic Area: Genetic Disease Product Name: SEL-302
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Details:
SEL-302 comprises ImmTOR in combination with MMA-101, and has the potential to mitigate unwanted immunogenicity to treat individuals with methylmalonic acidemia.
Lead Product(s): SEL-302
Therapeutic Area: Genetic Disease Product Name: SEL-302
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Details:
The partnership leverages Genovis’ proprietary immunoglobulin G protease, IdeXork, and Selecta’s ImmTOR platform to enable the dosing of transformative gene therapies in patients with pre-existing adeno-associated virus immunity and treat IgG-mediated autoimmune diseases.
Lead Product(s): Immunoglobulin G Protease
Therapeutic Area: Immunology Product Name: IdeXork
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Genovis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 21, 2021
Details:
Re-administration of AAV expressing MDR3 (VTX-803) treats progressive familial intrahepatic cholestasis type 3 (PFIC3) in juvenile Abcb4 -/- mice when co-administered with ImmTOR.
Lead Product(s): VTX-803,ImmTOR
Therapeutic Area: Genetic Disease Product Name: VTX-803
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
